Höglinger G - Search Results

1

Diagnosis and treatment of Parkinson´s disease (guideline of the German Society for Neurology).

Höglinger G; German Parkinson’s Guidelines Committee; Trenkwalder C. Höglinger G, et al. Neurol Res Pract. 2024 Jun 6;6(1):30. doi: 10.1186/s42466-024-00325-4. Neurol Res Pract. 2024. PMID: 38845028 Free PMC article.

2

Natural lipophilic inhibitors of mitochondrial complex I are candidate toxins for sporadic neurodegenerative tau pathologies.

Höllerhage M, Matusch A, Champy P, Lombès A, Ruberg M, Oertel WH, Höglinger GU. Höllerhage M, et al. Exp Neurol. 2009 Nov;220(1):133-42. doi: 10.1016/j.expneurol.2009.08.004. Epub 2009 Aug 13. Exp Neurol. 2009. PMID: 19682988

3

Neuregulin-1 receptor tyrosine kinase ErbB4 is upregulated in midbrain dopaminergic neurons in Parkinson disease.

Depboylu C, Höllerhage M, Schnurrbusch S, Brundin P, Oertel WH, Schrattenholz A, Höglinger GU. Depboylu C, et al. Neurosci Lett. 2012 Dec 7;531(2):209-14. doi: 10.1016/j.neulet.2012.10.050. Epub 2012 Nov 2. Neurosci Lett. 2012. PMID: 23123776

4

Trifluoperazine rescues human dopaminergic cells from wild-type α-synuclein-induced toxicity.

Höllerhage M, Goebel JN, de Andrade A, Hildebrandt T, Dolga A, Culmsee C, Oertel WH, Hengerer B, Höglinger GU. Höllerhage M, et al. Neurobiol Aging. 2014 Jul;35(7):1700-11. doi: 10.1016/j.neurobiolaging.2014.01.027. Epub 2014 Jan 28. Neurobiol Aging. 2014. PMID: 24559643

5

Memory deficits correlate with tau and spine pathology in P301S MAPT transgenic mice.

Xu H, Rösler TW, Carlsson T, de Andrade A, Bruch J, Höllerhage M, Oertel WH, Höglinger GU. Xu H, et al. Neuropathol Appl Neurobiol. 2014 Dec;40(7):833-43. doi: 10.1111/nan.12160. Neuropathol Appl Neurobiol. 2014. PMID: 24865638

6

Transcriptional and structural plasticity of tyrosine hydroxylase expressing neurons in both striatum and nucleus accumbens following dopaminergic denervation.

Depboylu C, Klietz M, Maurer L, Oertel WH, Kobayashi K, Weihe E, Höglinger GU, Schäfer MK. Depboylu C, et al. J Chem Neuroanat. 2014 Nov;61-62:169-75. doi: 10.1016/j.jchemneu.2014.10.003. Epub 2014 Oct 29. J Chem Neuroanat. 2014. PMID: 25451178

7

Tau silencing by siRNA in the P301S mouse model of tauopathy.

Xu H, Rösler TW, Carlsson T, de Andrade A, Fiala O, Hollerhage M, Oertel WH, Goedert M, Aigner A, Höglinger GU. Xu H, et al. Curr Gene Ther. 2014;14(5):343-51. doi: 10.2174/156652321405140926160602. Curr Gene Ther. 2014. PMID: 25687501

8

Psychosis in Parkinson's disease: identification, prevention and treatment.

Levin J, Hasan A, Höglinger GU. Levin J, et al. J Neural Transm (Vienna). 2016 Jan;123(1):45-50. doi: 10.1007/s00702-015-1400-x. Epub 2015 Apr 18. J Neural Transm (Vienna). 2016. PMID: 25894288 Review.

9

Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease.

Noelker C, Lu L, Höllerhage M, Vulinovic F, Sturn A, Roscher R, Höglinger GU, Hirsch EC, Oertel WH, Alvarez-Fischer D, Andreas H. Noelker C, et al. J Neurol Sci. 2015 Sep 15;356(1-2):129-36. doi: 10.1016/j.jns.2015.06.030. Epub 2015 Jun 17. J Neurol Sci. 2015. PMID: 26104567

10

The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach.

Levin J, Maaß S, Schuberth M, Respondek G, Paul F, Mansmann U, Oertel WH, Lorenzl S, Krismer F, Seppi K, Poewe W, Wenning G; PROMESA study group; Giese A, Bötzel K, Höglinger G. Levin J, et al. Among authors: hoglinger g. J Neural Transm (Vienna). 2016 Apr;123(4):439-45. doi: 10.1007/s00702-016-1507-8. Epub 2016 Jan 25. J Neural Transm (Vienna). 2016. PMID: 26809243 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

389 results

Search Page

Filters